Our News
17.07
2025
Pharmathen announces John Nason as incoming Group CEO, succeeding Dimitris Kadis
John Nason is appointed Group CEO, succeeding Dimitris Kadis, effective immediately. It is a mutual decision that comes after thoughtful discussions between Dimitris Kadis and the Board of Directors over the past year.
John Nason brings 30 years of global pharma leadership in operational roles at Teva, Bristol Myers Squibb, Novartis, and Sandoz. His experience will help to build on Pharmathen’s strategy and drive towards the growth potential of the organization, while ensuring stability and continuity of operations.
Thierry Bollore, Chairman of the Board of Directors, commented: We thank Dimitris for his leadership over more than 20 years, including six as CEO. Under Dimitris’ guidance, the company has doubled, driven by organic growth of the portfolio and new product launches. He was instrumental in the acquisition of CBL Patras, gaining access to the peptides market. Looking ahead, we are confident that John will guide Pharmathen to continued success.
Dimitris Kadis commented: It has been an amazing and rewarding journey with Pharmathen. I am very proud of what we have achieved in all these years. I am confident that, with the Board’s support and John Nason’s leadership, the best is yet to come for Pharmathen and its people. As a shareholder, I will continue to care for and, wherever I can, contribute to the further growth of the company.
John Nason commented: Pharmathen is an exceptional company with a clear strategy. The strength of the portfolio is reflected in the strong client demand, enough to potentially double the company size in the next 2-3 years. The leadership team and I will continue to invest in the teams, portfolio, and infrastructure to reach that target.
Pharmathen Press Release in Greek
Pharmathen Press Release in English
Media contact information
Please contact Natasha Kyriakaki, Pharmathen Head of Corporate Communication (nkyriakaki@pharmathen.com) for press inquiries.
About Pharmathen:
For 56 years, Pharmathen has been a pioneer in the field of Research & Development and pharmaceutical production. Driven by innovation, it leads in drug delivery technology, specializing in complex long-acting injectable (LAI) products. With 100 products available in more than 90 countries worldwide, it ranks among the 50 largest research-based pharmaceutical companies in Europe. Its development plan reaches €500 million by 2026, making it the largest private investor in Research & Development in Greece. At the heart of Pharmathen are its 1,600 employees, including 240 top researchers, who make a difference in people’s lives every day.